BioCryst Pharmaceuticals Inc. held its Annual Meeting of Stockholders on June 12, 2025. During the meeting, several proposals were addressed. Two directors, Steven K. Galson, M.D., MPH, and Alan G. Levin, were elected to the board. The ratification of Ernst & Young LLP as the independent registered public accountants for 2025 was approved. Additionally, an amendment to the Stock Incentive Plan, which increased the number of shares available for issuance by 11,000,000 shares, was also approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.